Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7780)	11/20/1998 3:25:00 PM
From: aknahow	Respond to of 17367

Antibiotic resistance work in the U.K. phls.co.uk Partial quote: "At the new Laboratory, where we will work closely with NHS and academic colleagues, with the British Society for Antimicrobial Chemotherapy and with the pharmaceutical industry, we recognize that development of new antibiotics is critical, just as is trying to extend the value of existing drugs" AND another quote from another page: The work of the new lab will include Monitoring patterns and trends in resistance, and relating these to the use and effectiveness of antibiotics in treating disease Evaluating new drugs for use against ‘superbugs' Conducting research into the fundamental bases of resistance and how resistances can be outmanoeuvred. Press release on the new laboratory Informaton on SMAC report